Aim: Switch all patients from the originator of Adalimumab (Humira) to Adalimumab Biosimilar (Imraldi / Amgevita).
Goal set by NHS England: 90% of all new patients switched within 3 months and 80%of all existing patients to be switched to a biosimilar within 12 months.
![](/storage/thumbs/707x528/Screenshot-2019-09-27-at-212533.png)